[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566786":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":52,"collaborators":20,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":20,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Institut Curie","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Prospective cohort involving repeated medical imaging with a new radiotracer (68Ga-FAPI-46)","EXPERIMENTAL","All patients of this study must have been previously enrolled in the HoMING cohort (NCT 04363983, sponsor APHP).",[13],"Drug: 68Ga-FAPI-46 for PET \u002F CT scan",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","68Ga-FAPI-46 for PET \u002F CT scan","Gallium 68-labeled fibroblast activation protein inhibitor (FAPI) used as radiotracer during PET imaging.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Nicolas Deleval","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Marie-Emmanuelle LEGRIER","CONTACT","0033156245765","drci.promotion@curie.fr",{"name":32,"role":28,"phone":33,"phoneExt":20,"email":30},"Sandra NESPOULOUS","0033147111654",[35],{"facility":36,"status":37,"city":38,"state":20,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Institut Curie -site Saint-Cloud","RECRUITING","Saint-Cloud","92210","France","FR",{"type":43,"coordinates":44},"Point",[45,46],2.20289,48.84598,{"lat":46,"lon":45},[49,51],{"name":50,"role":28,"phone":20,"phoneExt":20,"email":20},"Nicolas Deleval, MD",{"name":50,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":53,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100566786","phase-2-cutting-edge-imaging-with-pet-fapi-for-earlier-pancreatic-cancer-diagnosis-indigo-fapi-100566786",false,"NCT06659705","Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)","Cutting Edge Imaging for Earlier Pancreatic Cancer Diagnosis: Evaluation of Positron Emission Tomography (PET) With the Fibroblast Activation Protein Inhibitor (FAPI)","INDIGO-FAPI","Inclusion Criteria:\n\n1. Cyto\u002Fhistologically proven PDAC\n2. Non-metastatic proven PDAC on recent (\\\u003C 1 month) CT-scan and MRI\n3. Concomitant enrollment in the HoMING prospective cohort (Sponsor: AP-HP, NCT04363983)\n4. Age \\> 18 years old\n5. Affiliation to a social security scheme\n6. Signed informed consent\n\nExclusion Criteria:\n\n1. Protected adults (guardianship, curatorship or safeguarding justice)\n2. Pregnant or breastfeeding woman\n3. Women of childbearing potential not using one highly effective method of contraception","ALL","18 Years",{"count":65,"type":66},35,"ESTIMATED","INTERVENTIONAL",[69],"PHASE2","Assessment of the relevance of a new medical imaging test, FAPI PET, which could detect progression or relapse earlier than other tests currently available. Ultimately, it could enable early forms of pancreatic cancer to be detected and used for screening.\n\nIn addition to the usual examinations prescribed, FAPI PET scans will be repeated at several points in the treatment process.\n\nAll study patients must first have been included in the Homing cohort (NCT 04363983, APHP promotion). Clinical characteristics, judgement criteria and results of biological or imaging examinations carried out as part of this cohort will be shared.\n\nPatient follow-up and participation in the study ends when conventional imaging (CT and MRI) shows disease progression, relapse or death.",[72],"Pancreatic Ductal Adenocarcinoma (PDAC)",[74,75,76,77,78],"Fibroblast Activation Protein Inhibitor","Positron Emission Tomography","Pancreatic ductal adenocarcinoma","PDAC","FAPI","2026-04-10",{"date":81,"type":82},"2026-04-15","ACTUAL",{"date":84,"type":82},"2025-12-02",{"date":86,"type":66},"2030-08-08",{"name":5,"class":6},1]